ES3063926T3 - Combination comprising an mek inhibitor and a b-raf inhibitor - Google Patents

Combination comprising an mek inhibitor and a b-raf inhibitor

Info

Publication number
ES3063926T3
ES3063926T3 ES24175377T ES24175377T ES3063926T3 ES 3063926 T3 ES3063926 T3 ES 3063926T3 ES 24175377 T ES24175377 T ES 24175377T ES 24175377 T ES24175377 T ES 24175377T ES 3063926 T3 ES3063926 T3 ES 3063926T3
Authority
ES
Spain
Prior art keywords
inhibitor
raf
mek
combination
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES24175377T
Other languages
English (en)
Inventor
Melissa Dumble
Rakesh Kumar
Sylvie Laquerre
Peter Lebowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43876568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES3063926(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES3063926T3 publication Critical patent/ES3063926T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Una nueva combinación que comprende el inhibidor de MEK N-{3-[3-ciclopropil-5-(2-fluoro-4-iodofenilamino)-6,8-dimetil;-2,4,7-trioxo-3,4,6,7-tetrahidro-2H-pirido[4,3-d]pirimidin-1-il]fenil}acetamida, o una sal o solvato farmacéuticamente aceptable del mismo, con un inhibidor de B-Raf, en particular N-{3-[5-(2-amino-4-pirimidinil)-2-(1,1-dimetiletil)-1,3-tiazol-4-il]-2-fluorofenil}-2,6-difluorobencenosulfonamida o una sal farmacéuticamente aceptable del mismo, composiciones farmacéuticas que comprenden lo mismo y métodos para usar tales combinaciones y composiciones en el tratamiento de afecciones en las que la inhibición de MEK y/o B-Raf es beneficiosa, por ejemplo, cáncer. (Traducción automática con Google Translate, sin valor legal)
ES24175377T 2009-10-16 2010-10-15 Combination comprising an mek inhibitor and a b-raf inhibitor Active ES3063926T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25221309P 2009-10-16 2009-10-16

Publications (1)

Publication Number Publication Date
ES3063926T3 true ES3063926T3 (en) 2026-04-21

Family

ID=43876568

Family Applications (4)

Application Number Title Priority Date Filing Date
ES10824148T Active ES2745479T3 (es) 2009-10-16 2010-10-15 Combinación que comprende un inhibidor de MEK y un inhibidor de B-raf
ES24175377T Active ES3063926T3 (en) 2009-10-16 2010-10-15 Combination comprising an mek inhibitor and a b-raf inhibitor
ES19174594T Active ES2930157T3 (es) 2009-10-16 2010-10-15 Combinación que comprende un inhibidor de MEK y un inhibidor de B-Raf
ES22189749T Active ES2986037T3 (es) 2009-10-16 2010-10-15 Combinación que comprende un inhibidor de MEK y un inhibidor de B-Raf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES10824148T Active ES2745479T3 (es) 2009-10-16 2010-10-15 Combinación que comprende un inhibidor de MEK y un inhibidor de B-raf

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES19174594T Active ES2930157T3 (es) 2009-10-16 2010-10-15 Combinación que comprende un inhibidor de MEK y un inhibidor de B-Raf
ES22189749T Active ES2986037T3 (es) 2009-10-16 2010-10-15 Combinación que comprende un inhibidor de MEK y un inhibidor de B-Raf

Country Status (35)

Country Link
US (3) US8703781B2 (es)
EP (5) EP4706770A2 (es)
JP (1) JP5718929B2 (es)
KR (1) KR101729116B1 (es)
CN (1) CN102655753B (es)
AU (1) AU2010306653B2 (es)
BR (1) BR112012008854B8 (es)
CA (1) CA2775803C (es)
CL (1) CL2012000964A1 (es)
CO (1) CO6531498A2 (es)
CR (1) CR20120155A (es)
CY (1) CY1122013T1 (es)
DK (4) DK4397376T3 (es)
DO (1) DOP2012000091A (es)
EA (1) EA020589B1 (es)
ES (4) ES2745479T3 (es)
FI (2) FI4159217T3 (es)
HR (3) HRP20260236T1 (es)
HU (3) HUE060206T2 (es)
IL (1) IL219073A (es)
LT (4) LT2488033T (es)
MA (1) MA33746B1 (es)
ME (1) ME03497B (es)
MX (1) MX2012004413A (es)
MY (1) MY174759A (es)
NZ (1) NZ598913A (es)
PE (1) PE20121093A1 (es)
PH (1) PH12012500742A1 (es)
PL (4) PL4159217T3 (es)
PT (4) PT4397376T (es)
RS (4) RS59181B1 (es)
SI (3) SI4397376T1 (es)
UA (1) UA105064C2 (es)
WO (1) WO2011047238A1 (es)
ZA (1) ZA201202612B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2303021T3 (en) 2008-06-16 2019-04-08 Univ Tennessee Res Found RELATIONSHIPS FOR TREATING CANCER
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
EP2545187B1 (en) * 2010-03-09 2018-09-05 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
EP2635286A4 (en) * 2010-11-05 2014-11-12 Glaxosmithkline Ip No 2 Ltd METHOD FOR THE TREATMENT OF CANCER
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
EP2791171A1 (en) 2011-12-16 2014-10-22 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
KR20140107576A (ko) * 2011-12-22 2014-09-04 글락소스미스클라인 엘엘씨 Braf 저해제 및/또는 mek 저해제와 magea3 면역치료제를 이용한 암 치료 방법
EP2830664A1 (en) * 2012-03-30 2015-02-04 Takeda Pharmaceutical Company Limited Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma
HRP20211817T1 (hr) * 2012-09-04 2022-03-04 Novartis Ag Postupak adjuvantnog liječenja raka
BR112015009134A2 (pt) * 2012-10-25 2017-07-04 Glaxosmithkline Llc combinação
MA38121A1 (fr) * 2012-11-30 2016-10-31 Glaxosmithkline Llc Nouvelle composition pharmaceutique
CN103965170A (zh) * 2013-01-24 2014-08-06 通化济达医药有限公司 苯磺酰胺吡唑激酶抑制剂
CN105163584B (zh) * 2013-03-05 2019-06-04 田纳西大学研究基金会 用于治疗癌症的化合物
WO2014193898A1 (en) * 2013-05-31 2014-12-04 Merck Sharp & Dohme Corp. Combination therapies for cancer
CN105658206A (zh) * 2013-06-03 2016-06-08 诺华股份有限公司 抗pd-l1抗体与mek抑制剂和/或braf抑制剂的组合
CN104540822B (zh) * 2013-07-08 2016-08-31 杭州普晒医药科技有限公司 达拉菲尼甲磺酸盐的晶型及其制备方法
WO2015059677A1 (en) * 2013-10-26 2015-04-30 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer
CN103588767B (zh) * 2013-11-20 2016-01-20 苏州明锐医药科技有限公司 达拉菲尼的制备方法
MX2016007653A (es) * 2013-12-12 2016-10-13 Novartis Ag Combinaciones de trametinib, panitumumab y dabrafenib para el tratamiento del cancer.
ES2660989T3 (es) 2013-12-28 2018-03-27 Guardant Health, Inc. Métodos y sistemas para detectar variantes genéticas
WO2015105822A1 (en) * 2014-01-07 2015-07-16 Glaxosmithkline Llc Cancer treatment method
RU2733393C9 (ru) 2014-05-06 2021-09-09 Джи Ти Икс, ИНК. Соединения для лечения рака
KR101629184B1 (ko) 2014-12-10 2016-06-13 현대오트론 주식회사 Autosar 플랫폼에서의 eeprom 처리속도 향상을 위한 주기함수 호출 방법
US20190008859A1 (en) 2015-08-21 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
CN110022878A (zh) * 2016-11-03 2019-07-16 密执安大学评议会 Egfr/pi3k的小分子双重抑制剂及其用途
WO2020079581A1 (en) 2018-10-16 2020-04-23 Novartis Ag Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN112294965B (zh) * 2019-07-26 2023-03-14 苏州亚盛药业有限公司 Mdm2抑制剂的药物组合物及其在预防和/或治疗疾病中的用途
EP4725489A2 (en) 2019-08-02 2026-04-15 OneHealthCompany, Inc. Treatment of canine cancers
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CN114981298B (zh) 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US12014835B2 (en) 2020-02-19 2024-06-18 Vanderbilt University Methods for evaluating therapeutic benefit of combination therapies
US20230084515A1 (en) * 2020-02-19 2023-03-16 Vanderbilt University Therapeutic methods and compositions for treating cancer using braf and/or mek inhibitor combination therapy
CN117321418A (zh) 2021-03-18 2023-12-29 诺华股份有限公司 癌症生物标志物及其使用方法
WO2023081676A1 (en) * 2021-11-02 2023-05-11 Verastem, Inc. Methods of treating abnormal cell growth
US20250032494A1 (en) 2021-12-06 2025-01-30 My Personal Therapeutics Ltd A combination treatment for cancer
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
CN121712509A (zh) 2023-05-04 2026-03-20 锐新医药公司 用于ras相关疾病或病症的组合疗法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
IL327306A (en) 2023-10-12 2026-05-01 Revolution Medicines Inc Macrocyclic RAS inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US7189745B1 (en) 1999-11-22 2007-03-13 Smithkline Beecham Corporation Compounds
DE102004018198A1 (de) * 2004-04-15 2005-11-03 Merck Patent Gmbh Sulfonamide
PT2298768E (pt) * 2004-06-11 2012-12-05 Japan Tobacco Inc Derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetra-hidro-2hpirido[ 2,3-d]pirimidina e compostos relacionados para o tratamento do cancro
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
WO2008120004A1 (en) 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
CA2924418A1 (en) 2007-07-30 2009-02-05 Jean-Michel Vernier Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds

Also Published As

Publication number Publication date
DK3560498T3 (da) 2022-11-14
EP4397376A3 (en) 2024-10-30
FI4159217T3 (fi) 2024-08-15
LT2488033T (lt) 2019-09-10
CN102655753B (zh) 2015-11-25
ZA201202612B (en) 2013-09-25
ME03497B (me) 2020-04-20
EP3560498A1 (en) 2019-10-30
JP2013508294A (ja) 2013-03-07
WO2011047238A1 (en) 2011-04-21
AU2010306653B2 (en) 2013-10-24
ES2986037T3 (es) 2024-11-08
EP4397376B1 (en) 2025-11-26
RS67767B1 (sr) 2026-03-31
ES2745479T3 (es) 2020-03-02
EP2488033A1 (en) 2012-08-22
PH12012500742A1 (en) 2015-12-11
PE20121093A1 (es) 2012-09-04
CO6531498A2 (es) 2012-09-28
EP4159217A1 (en) 2023-04-05
EP4706770A2 (en) 2026-03-11
RS63702B1 (sr) 2022-11-30
KR101729116B9 (ko) 2026-02-05
SI4397376T1 (sl) 2026-04-30
CN102655753A (zh) 2012-09-05
HRP20260236T1 (hr) 2026-04-10
RS59181B1 (sr) 2019-10-31
LT4397376T (lt) 2026-03-10
US8952018B2 (en) 2015-02-10
LT3560498T (lt) 2022-11-25
PL2488033T3 (pl) 2019-12-31
EA020589B1 (ru) 2014-12-30
HRP20221304T1 (hr) 2022-12-23
CY1122013T1 (el) 2020-10-14
CA2775803C (en) 2017-11-21
CL2012000964A1 (es) 2012-08-31
DK4397376T3 (da) 2026-02-23
HUE067723T2 (hu) 2024-11-28
JP5718929B2 (ja) 2015-05-13
KR101729116B1 (ko) 2017-05-02
US20150111904A1 (en) 2015-04-23
MX2012004413A (es) 2012-05-08
AU2010306653A1 (en) 2012-05-10
CA2775803A1 (en) 2011-04-21
EP3560498B1 (en) 2022-08-17
SI2488033T1 (sl) 2019-10-30
MA33746B1 (fr) 2012-11-01
DOP2012000091A (es) 2013-09-15
US20120196879A1 (en) 2012-08-02
EP4397376A2 (en) 2024-07-10
PT4159217T (pt) 2024-08-12
DK4159217T3 (da) 2024-08-12
BR112012008854A2 (pt) 2015-09-22
PL4159217T3 (pl) 2024-09-30
EP4159217B1 (en) 2024-05-22
KR20120104547A (ko) 2012-09-21
PT2488033T (pt) 2019-09-10
EP2488033B1 (en) 2019-06-12
FI4397376T3 (fi) 2026-02-24
UA105064C2 (uk) 2014-04-10
PT3560498T (pt) 2022-11-03
RS65800B1 (sr) 2024-08-30
US8703781B2 (en) 2014-04-22
EA201290149A1 (ru) 2012-11-30
EP2488033A4 (en) 2014-04-30
PL4397376T3 (pl) 2026-03-30
MY174759A (en) 2020-05-13
PL3560498T3 (pl) 2022-12-12
IL219073A (en) 2016-05-31
SI4159217T1 (sl) 2024-09-30
ES2930157T3 (es) 2022-12-07
BR112012008854B8 (pt) 2021-05-25
IL219073A0 (en) 2012-06-28
DK2488033T3 (da) 2019-09-02
NZ598913A (en) 2013-11-29
US20140187566A1 (en) 2014-07-03
HRP20191617T1 (hr) 2019-12-13
BR112012008854B1 (pt) 2020-12-29
LT4159217T (lt) 2024-08-26
HUE060206T2 (hu) 2023-02-28
HUE046139T2 (hu) 2020-02-28
CR20120155A (es) 2012-07-05
PT4397376T (pt) 2026-02-24

Similar Documents

Publication Publication Date Title
CR20120155A (es) Combinacion
PY2052241A (es) Inhibidores heterocíclicos de la cinasa rip1
HK1216231A1 (zh) Anti-pd-l1抗体及mek抑制剂及/或braf抑制剂的混合物
CL2008001038A1 (es) Uso de una composicion que comprende un antagonosta h1, y un compuesto anti-tnf alfa para tratar conjuntivitis alegica o rinitis alergiva en un sujeto humano
CR10226A (es) Combinaciones del inhibidor de ang2 y vegf
CR9901A (es) Combinaciones antineoplasicas con inhibidor de objetivo de rapamicina en mamiferos, herceptina, y/o hki-272
CR20110339A (es) Compuestos útiles para inhibir chk1
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
DOP2013000097A (es) Composiciones y métodos para el tratamiento de la mielofibrosis
BR112015009134A2 (pt) combinação
CL2007002018A1 (es) Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular.
CL2012000755A1 (es) Compuestos especificos 2-(3-amino-1-(2,4-difluorofenil)-1h-1,2,4-triazol-5-il)-n-metil-4,5-dihidrobenzeno(b) tieno(2,3-d)oxepina-8-carboxamida, inhibidor de la ctividad de la quinasa p13; composicon farmaceutica que lo comprende; kit farmaceutico que incluye a la composicion, y su uso para el tratamiento o profilaxis del cancer.
AR048819A1 (es) Metodos sinergicos y composiciones para el tratamiento del cancer
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
CL2011001299A1 (es) Compuestos derivados de benzotiazoles; composicion farmaceutica; y su uso como inhibidores de raf para el tratamiento o profilaxis del cancer.
CL2007002967A1 (es) Forma cristalina a del compuesto 4-[3-(4-ciclopropancarbonil-piperazin-1-carbonil)-4-fluoro-bencil]-2h-ftalazin-1-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un
AR073563A1 (es) Terapia de combinacion para el tratamiento de diabetes y estados relacionados
CL2007003523A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
GT201200038A (es) Composicion para tratar la fibrosis quistica
EA201270537A1 (ru) Комбинация
CL2011002233A1 (es) Metodo para tratar o prevenir el cancer, que comprende administrar una combinacion farmaceutica sinergica de: a) (s)-n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)-6-metoxifenil)-1-(2,3-dihidroxipropil)ciclopropan-1-sulfonamida y b) 3-(6,7-bis(2-metoxietoxi)quinazolin-4-ilamino)benzonitrilo; composicion farmaceutica; y kit farmaceutico.
DOP2008000053A (es) Inhibidores de akt(proteinas cinasa b)
CL2013003125A1 (es) Compuestos derivados de isoxazolinas inhibidores mps; composicion farmaceutica que los comprende; kit farmaceutico; y uso en el tratamiento de una enfermedad tales como osteoartritis, artritis reumatoide, artritis juvenil, artritis psoriasica, lupus eritematoso sistemico, entre otras.
BRPI1011768A8 (pt) agentes para o tratamento e/ou profilaxia de um distúrbio, e de uma doença, composição farmacêutica, kit, derivado de tiazol, composto, combinação, e, uso de um derivado de tiazol
BR112017016497A2 (pt) composições e métodos para metabolismo muscular melhorado